Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

Active:	No
Cancer Type:	Lung Cancer Unknown Primary	NCT ID:	NCT02486718
Trial Phases:	Phase III	Protocol IDs:	GO29527 (primary) NCI-2015-01731
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Hoffmann-La Roche
NCI Full Details:	http://clinicaltrials.gov/show/NCT02486718

Summary

This is a Phase III, global, multicenter, open-label, randomized study to compare the
efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A)
treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA
non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured
by disease-free survival (DFS) as assessed by the investigator and overall survival (OS).
Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will
be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.

Treatment Sites in Georgia

Central Georgia Cancer Care, PC - Macon
800 First Street
Suite 410
Macon, GA 31201
478-743-7068
www.centralGeorgiacancercare.com

Study Coordinator:

Melissa Shaw

Doctors:

Ahmad H. Al-Hajj MD

Bruce T. Burns MD

Linda K. Hendricks MD

Frederick M. Schnell MD, FACP

Abeer N. AbouYabis MD

Bradley T. Sumrall MD

Harry F. Moore, Jr. MD

Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
919 South Broad Street
Thomasville, GA 31792
www.archbold.org

Study Coordinator:

Tiffany Woolum
229-584-5417

Doctors:

Brian E. Gaupp MD, PhD

Amanda D. May MD

Josh Simmons

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.